Related Experiment Videos
Wisconsin cystic fibrosis chest radiograph scoring system
M R Weatherly1, C G Palmer, M E Peters
1University of Wisconsin, Madison.
Insights
A new Wisconsin system for cystic fibrosis (CF) chest X-rays offers improved sensitivity for detecting early lung disease. This validated scoring system aids in monitoring disease progression and evaluating new CF therapies in young children.
Area of Science:
- Radiology
- Pulmonology
- Medical Informatics
Background:
- Recent advances in cystic fibrosis (CF) diagnosis and treatment necessitate updated clinical scoring systems.
- Existing chest radiograph scoring systems lack sensitivity for mild lung disease in longitudinal CF studies.
- Objective pulmonary disease measurement is crucial for tracking CF progression, especially in infants.
Purpose of the Study:
- To develop a novel, sensitive, and reproducible radiographic scoring system for cystic fibrosis (CF) lung disease.
- To create a tool for evaluating therapies targeting early-stage CF.
- To improve the assessment of pulmonary disease severity and progression in young children with CF.
Main Methods:
- Applied multiattribute utility theory and mathematical modeling for component weighting.
- Utilized a panel of expert radiologists in cystic fibrosis radiology.
- Developed and validated the system in three phases, comparing it to the Brasfield method.
- Assessed inter-rater reliability (Kendall coefficient of concordance = 0.714) and sensitivity to disease progression.
Main Results:
- The Wisconsin system demonstrated reliable and convenient application for reproducible scoring.
- The system showed good agreement among four independent raters.
- The Wisconsin system detected greater score differences with disease progression compared to the Brasfield method.
- The system effectively identified progression from normality to mild lung disease.
Conclusions:
- The Wisconsin system is a sensitive and reproducible tool for assessing pulmonary disease in young children with cystic fibrosis.
- It is superior to previous methods for evaluating therapies aimed at modifying early CF disease course.
- The system is well-suited for longitudinal clinical studies involving infants and children with CF.
Abstract:
A new clinical scoring system for patients with cystic fibrosis is needed because of recent advances in diagnosis and treatment which have changed the course of this disease. Chest radiograph scoring is the best objective measure of pulmonary disease for longitudinal studies beginning with infants; however, based on pilot studies, previous scoring systems are not sensitive enough in discriminating between degrees of mild lung disease. Therefore, a new radiographic scoring system was developed with the goal of achieving both sensitivity and reproducibility. This objective was pursued by applying multiattribute utility theory, using a panel of interpreters with expertise in cystic fibrosis radiology, and employing mathematical modeling techniques to weight the various components. The system was developed and validated in three phases including comparison to the Brasfield method of quantitative radiology. The data demonstrate that the new system can be applied reliably and conveniently to generate reproducible scores of pulmonary disease severity. Evaluation of the scores by four independent raters using chest radiographs from 61 patients at an average age of 8.37 years revealed good agreement with a .714 Kendall coefficient of concordance. Assessment of serial changes over time was performed using a group of 176 chest radiographs from 25 patients ranging from 4 weeks to 6 years old; this showed that the Wisconsin system generates score differences that are greater in magnitude with disease progression compared with the Brasfield method. Therefore, the new method is more sensitive to progression of mild disease and should be superior to prior radiographic scoring systems for evaluating therapies designed to modify the early course of disease. The Wisconsin system is designed to be useful in longitudinal clinical studies involving young children with cystic fibrosis and is capable to detecting progression from normality to mild lung disease.